25
years clinical research experience
500
clinical trials phase I-IV
300
epidemiology RWE projects
Services
harnessing end-to-end clinical and epidemiology solutions
Combining clinical excellence, epidemiological expertise, and a regional focus to advance vaccine development and deliver impactful outcomes worldwide.
Clinical and Epidemiology Experts
With 300 staff and over 25 years of collective experience, we provide seamless integration of epidemiological expertise with clinical trial execution.
Global reach in vaccines and infectious disease
Headquartered in Europe, with regional hubs in Africa, Latin America, North America, and Southeast Asia, P95 operates on five continents, providing tailored solutions across 40 countries.
Committed to flexibility, client focus, and excellence
Our shared values drive us to deliver solutions that make a meaningful impact on public health worldwide.
africa & LMICs
Impactful outcomes in even the most challenging environments, including in Africa and low-to-middle-income countries (LMICs).
Our Vision
Our Mission
Our purpose
To pioneer global development of safe and effective vaccines.
To be the world’s favored partner in clinical research and epidemiology supporting vaccine development and use.
To make a difference to global health.
Your Trusted Guide in Vaccine and Infectious Disease Research
Partner with a trusted CRO with over 25 years of experience in clinical resreach and epidemiology.
What we do
Discover Our full range of solutions
From Phase I-IV clinical trials to epidemiological research and non-interventional studies, we provide end-to-end support in vaccines and infectious diseases — study design, site identification, trial management, safety mananagement, data analysis, and writing.
Clinical Trial Delivery
P95 provides comprehensive clinical trial services for vaccines and infectious diseases, guiding projects from early to late phase trials and ensuring high-quality results that meet regulatory and global standards.
Epidemiology and RWE Solutions
With deep expertise in epidemiology, P95 supports the design and execution of non-interventional studies and real-world data analysis for vaccines & infectious diseases, generating critical insights into disease burden, vaccine effectiveness, treatment outcomes, and healthcare resource utilization.
Africa and LMICs
Specializing in clinical and epidemiological research in Africa, LMICs, and other underserved regions, as well as traditional research locations, P95 combines global standards with localized expertise for successful project delivery in challenging environments.
Data, analysis and writing
P95’s data management, biostatistics, safety management and medical writing teams ensure data integrity and insightful analysis for vaccines and drugs across all stages of development, from protocol writing, eCRF design and database management, to pharmacovigilance, complex statistical reporting, and regulatory compliance and to publications and study reports.
trusted by global organizations
Testimonials
Client Feedback
Discover how our collaborative approach and deep expertise have helped our clients achieve impactful outcomes and navigate complex challenges.
OUR news
Latest from News
Stay up-to-date with our latest insights, industry news, and project milestones that shape the future of clinical research
P95 At World Vaccine Congress Europe 2024
This October, the P95 team attended and exhibited at Europe's largest vaccine event, the World Vaccine Congress Europe...
P95 Webinar: Insights to conducting clinical trials in Africa
Join P95 for its webinar on Insights to conducting clinical trials in Africa, on 5 November.
Effect of pneumococcal conjugate vaccines on viral respiratory infections: Systematic Literature Review
In addition to preventing pneumococcal disease, emerging evidence indicates that pneumococcal conjugate vaccines (PCVs) might indirectly reduce viral respiratory tract infections (RTIs) by affecting pneumococcal-viral interactions.